Nearly half of advertisers admit they don’t currently have the right balance between online and offline
A large portion of marketers globally (46%) don’t have the right balance and synergies between digital and offline media, while three quarters (76%) still struggle with cross-channel measurement. That’s according to the latest annual state of marketing study, Getting Media Right: Marketing in Motion, released recently by Kantar.
2020 is set to see a significant rise in digital ad spend, as marketers look to optimise their media mix. 84% of marketers plan to increase their investment in online video advertising over the next 12 months, while 70% plan to increase spend on social media networks and 63% plan to increase spend on podcasts. This is in sharp contrast to print media, where 70% of marketers say they will decrease spend in magazines, while 66% will reduce their investment in newspaper advertising.
Despite the projected growth in online advertising, digital measurement remains a challenge for marketers, with blind spots such as ‘walled gardens’ impacting the ability to understand cross-channel performance. This leaves many advertisers in the dark about the performance of their brand across channels.
Now in its sixth year, Getting Media Right examines the current state of marketing in a fast-moving connected world, and is based on in-depth survey feedback from nearly 500 senior marketers spanning advertiser brands, media publishers and agencies globally. It reveals an industry that continues to diversify its usage of different media contexts, yet requires better understanding of how ideas, content and media channels work together to achieve their goals of driving short-term sales and long-term brand growth.
Key findings from the study include:
• The short-term vs. long-term dilemma comes to a head. Almost all marketers (including 88% of advertisers) now recognise the importance of balancing short-term sales with long-term brand building. However, still only 54% of marketers are using both short and long-term measurement; 38% still rely solely on short-term sales results.
• Marketers still struggle with integrated campaigns. One quarter of advertisers (25%) have failed to integrate their marketing organisations, and 27% of advertisers do not have integrated strategies across media and non-media activities.
• Programmatic targeting continues to grow. Four in five marketers (80%) currently use programmatic targeting for their campaigns – and that is expected to reach 90% in 2020. But still nearly one in three advertisers aren’t confident they’re successfully targeting the right audiences.
• Cookieless advertising could leave marketers in the dark. The majority of the industry – nearly half of agencies and almost three-quarters of advertisers – haven’t begun preparations for a cookieless world, leaving many concerned about how such change will impact the industry.
• Almost one third of advertisers aren’t confident they understand the impact of context. Nearly two thirds of marketers agree that developing custom content is an imperative, but when it comes to understanding how context impacts creative executions, there’s still a gap. More insight is required into how specific content needs to be tailored to specific contexts to improve message receptivity.
“While the rapid growth in digital ad spend comes as no surprise, this new research indicates that marketers still have a long way to go to when it comes to cross-channel measurement and proving ROI,” said Jane Ostler, Global Head of Media Effectiveness, Kantar’s Media Domain. “The next 12 months will see huge changes for the industry, with the rise of newer channels, such as podcasts and advanced TV, and the move away from cookies set to transform the way advertisers target and measure campaigns. Marketers should aim for the best of both worlds: they need to create a framework to monitor impact on business and brand metrics. That means harmonising measurement tools, building an infrastructure that enables measurement across the diverse marketing mix, and creating meaningful insights to improve performance across all channels.”
sildenafil 50mg uk – sildenafil canada sildenafil 100mg sale
buy prednisolone 20mg online – buy gabapentin 100mg pills buy tadalafil 5mg pill
augmentin 1000mg ca – order cialis 20mg without prescription order cialis 20mg generic
order bactrim 960mg for sale – sildenafil 150mg uk viagra 150mg tablet
buy cephalexin 500mg generic – clindamycin price erythromycin brand
buy fildena pills – ivermectin 12mg pills for humans cost of stromectol
order budesonide online cheap – purchase budesonide online cheap buy generic disulfiram 500mg
order ceftin sale – generic cialis 20mg tadalafil 10mg tablet
acillin uk – cialis 5mg brand cialis 40mg cheap
generic amoxicillin 250mg – brand amoxil 1000mg vardenafil order
generic stromectol – ivermectin 3mg over the counter order levitra 10mg generic
order doxycycline 200mg without prescription – doxycycline 200mg pill buy tadalafil 10mg without prescription
cialis order – fda approved canadian online pharmacies order modafinil 100mg without prescription
buy prednisone 20mg pill – home remedies for ed erectile dysfunction order accutane generic
brand amoxil 1000mg – zithromax 250mg pill buy sildenafil generic
brand prednisolone 10mg – purchase prednisolone generic viagra 150mg uk
فلوکستین در واقع نوعی داروی ضد
افسردگی است. این دارو از مهارکننده های انتخابی
باز جذب سرتونین در بدن به حساب می
آید. معمولا از فلوکستین در درمان افسردگی،
پنیک اتک، پرخوری عصبی و یا حتی سندروم پس از قاعدگی (PMS) استفاده می شود.
پروزاک یا همان فلوکستین اولین بار در سال
1988 در ایالات متحده ظاهر شد
و به یکی از داروهای ضد افسردگی که به طور گسترده در این کشور تجویز می شد تبدیل شد.
اگرچه داروهای جدیدتری مانند سرترالین و سیتالوپرام اکنون در دسترس هستند اما این دارو
همچنان در بین افراد در معرض اختلالات و تنش های
روحی بسیار محبوب است.
فلوکستین دارویی تجویزی است.
به شکلهای کپسول، کپسول با تأخیر در انتشار، قرص و محلول در
بازار موجود است. همه اشکال از طریق بلع مصرف
میشوند. (کپسول تأخیر در انتشار در بدن شما کندتر منتشر میشود.) کپسول خوراکی فلوکستین
به صورت داروهای با نام تجاری Prozac
و Prozac Weekly نیز موجود است. به عنوان داروی عمومینیز در بازار موجود
است. داروهای عمومیمعمولاً قیمت
کمتری نسبت به نسخههای مارک دار دارند.
order furosemide 40mg online cheap – order doxycycline 100mg online cheap stromectol online pharmacy
hydroxychloroquine 200mg oral – buy chloroquine pill baricitinib online buy
buy metformin 1000mg online – order amlodipine 5mg generic norvasc price
order lisinopril 5mg pills – order atenolol 100mg pill buy atenolol 50mg without prescription
levitra 10mg oral – buy pregabalin 150mg generic order clomiphene 50mg generic
order albuterol without prescription – generic albuterol 4mg dapoxetine over the counter
buy synthroid 75mcg sale – order plaquenil generic plaquenil 200mg without prescription
Link exchange is nothing else except it is simply placing the other person’s weblog link on your page at proper place and other person will also do similar for you.
order cialis 40mg for sale – cialis price sildenafil 150mg canada
deltasone 20mg pills – buy xenical sale buy amoxil online cheap
buy generic diltiazem – brand azithromycin neurontin us
order lasix 40mg generic – order zovirax 800mg generic doxycycline 200mg over the counter
oral cenforce 50mg – zetia order online buy domperidone generic
sildenafil next day delivery – sildenafil 50mg for sale tadalafil usa
buy provigil 100mg online – rhinocort drug budesonide online buy
buy accutane 20mg sale – accutane 20mg us order tetracycline 250mg generic
cheap tadalafil online tadalafil 5 mg tablet coupon
https://buynolvadex.store/# tamoxifen reviews
[url=https://buymetformin.best/#]metformin buy online usa[/url] buy metformin without prescription cheap
lipitor 200 mg lipitor generic drug
buy cyclobenzaprine 15mg online cheap – buy gloperba online inderal pills
https://buynolvadex.store/# nolvadex online
https://buynolvadex.store/# tamoxifen skin changes